{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T16:01:19Z","timestamp":1790352079193,"version":"4.1.0"},"reference-count":47,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,7,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Broad genomic analyses among thyroid histologies have been described from relatively small cohorts.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Investigate the molecular findings across a large, real-world cohort of thyroid fine-needle aspiration (FNA) samples.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Retrospective analysis of RNA sequencing data files.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Clinical Laboratory Improvement Amendments laboratory performing Afirma Genomic Sequencing Classifier (GSC) and Xpression Atlas (XA) testing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>A total of 50 644 consecutive Bethesda III-VI nodules.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>None.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Molecular test results.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 48 952 Bethesda III\/IV FNAs studied, 66% were benign by Afirma GSC. The prevalence of BRAF V600E was 2% among all Bethesda III\/IV FNAs and 76% among Bethesda VI FNAs. Fusions involving NTRK, RET, BRAF, and ALK were most prevalent in Bethesda V (10%), and 130 different gene partners were identified. Among small consecutive Bethesda III\/IV sample cohorts with one of these fusions and available surgical pathology excision data, the positive predictive value of an NTRK or RET fusion for carcinoma or noninvasive follicular thyroid neoplasm with papillary-like nuclear features was &amp;gt;95%, whereas for BRAF and ALK fusions it was 81% and 67%, respectively. At least 1 genomic alteration was identified by the expanded Afirma XA panel in 70% of medullary thyroid carcinoma classifier\u2013positive FNAs, 44% of Bethesda III or IV Afirma GSC suspicious FNAs, 64% of Bethesda V FNAs, and 87% of Bethesda VI FNAs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>This large study demonstrates that almost one-half of Bethesda III\/IV Afirma GSC suspicious and most Bethesda V\/VI nodules had at least 1 genomic variant or fusion identified, which may optimize personalized treatment decisions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab304","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T15:41:52Z","timestamp":1621438912000},"page":"2198-2207","source":"Crossref","is-referenced-by-count":64,"title":["Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0355-030X","authenticated-orcid":false,"given":"Mimi I","family":"Hu","sequence":"first","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-0100","authenticated-orcid":false,"given":"Steven G","family":"Waguespack","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6609-5135","authenticated-orcid":false,"given":"Chrysoula","family":"Dosiou","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Gerontology, & Metabolism, Stanford University School of Medicine, Stanford, CA 94305, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9737-7159","authenticated-orcid":false,"given":"Paul W","family":"Ladenson","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8436-392X","authenticated-orcid":false,"given":"Masha J","family":"Livhits","sequence":"additional","affiliation":[{"name":"Department of Surgery, Section of Endocrine Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2629-2289","authenticated-orcid":false,"given":"Lori J","family":"Wirth","sequence":"additional","affiliation":[{"name":"Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1036-6367","authenticated-orcid":false,"given":"Peter M","family":"Sadow","sequence":"additional","affiliation":[{"name":"Department of Pathology, Head and Neck Pathology Subspecialty, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-3901","authenticated-orcid":false,"given":"Jeffrey F","family":"Krane","sequence":"additional","affiliation":[{"name":"Department of Pathology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan C","family":"Stack","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology-Head and Neck Surgery, Southern Illinois University School of Medicine, Springfield, IL 62794, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7918-9739","authenticated-orcid":false,"given":"Mark E","family":"Zafereo","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Z","family":"Ali","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Radiology, The Johns Hopkins Hospital, Baltimore, MD 21287, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9045-0202","authenticated-orcid":false,"given":"Steven P","family":"Weitzman","sequence":"additional","affiliation":[{"name":"Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Hao","sequence":"additional","affiliation":[{"name":"Research and Development, Veracyte, South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua E","family":"Babiarz","sequence":"additional","affiliation":[{"name":"Research and Development, Veracyte, South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia C","family":"Kennedy","sequence":"additional","affiliation":[{"name":"Departments of Clinical Affairs, Medical Affairs, Research and Development, Veracyte, Inc., South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4183-7387","authenticated-orcid":false,"given":"Richard T","family":"Kloos","sequence":"additional","affiliation":[{"name":"Department of Medical Affairs, Veracyte, Inc., South San Francisco, CA 94080, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"issue":"11","key":"2021122204430246300_CIT0001","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer","volume":"19","author":"American Thyroid Association Guidelines Taskforce on Thyroid N, Differentiated Thyroid C","year":"2009","journal-title":"Thyroid"},{"issue":"3","key":"2021122204430246300_CIT0002","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1097\/SLA.0000000000003580","article-title":"The American Association of Endocrine Surgeons guidelines for the definitive surgical management of thyroid disease in adults","volume":"271","author":"Patel","year":"2020","journal-title":"Annals of surgery"},{"key":"2021122204430246300_CIT0003","article-title":"Thyroid carcinoma","volume-title":"NCCN Clinical Practice Guidelines in Oncology","author":"NCCN Clinical Practice Guidelines in Oncology"},{"issue":"1","key":"2021122204430246300_CIT0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid."},{"issue":"9","key":"2021122204430246300_CIT0005","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamasurg.2018.1153","article-title":"Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules","volume":"153","author":"Patel","year":"2018","journal-title":"JAMA Surg"},{"key":"2021122204430246300_CIT0006","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3389\/fendo.2019.00612","article-title":"Analytical and clinical validation of expressed variants and fusions from the whole transcriptome of thyroid FNA Samples","volume":"10","author":"Angell","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"7","key":"2021122204430246300_CIT0007","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/cncy.22300","article-title":"The Afirma Xpression Atlas for thyroid nodules and thyroid cancer metastases: insights to inform clinical decision-making from a fine-needle aspiration sample","volume":"128","author":"Krane","year":"2020","journal-title":"Cancer Cytopathol."},{"issue":"10","key":"2021122204430246300_CIT0008","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/thy.2020.0086","article-title":"Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases","volume":"30","author":"Xu","year":"2020","journal-title":"Thyroid."},{"key":"2021122204430246300_CIT0009","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.isci.2019.09.030","article-title":"Genetic landscape of somatic mutations in a large cohort of sporadic medullary thyroid carcinomas studied by next-generation targeted sequencing","volume":"20","author":"Ciampi","year":"2019","journal-title":"Iscience."},{"issue":"13","key":"2021122204430246300_CIT0010","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2021122204430246300_CIT0011","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/path.5005","article-title":"Genetic landscape of papillary thyroid carcinoma in the Chinese population","volume":"244","author":"Liang","year":"2018","journal-title":"J Pathol."},{"issue":"3","key":"2021122204430246300_CIT0012","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell"},{"key":"2021122204430246300_CIT0013","doi-asserted-by":"crossref","first-page":"15533","DOI":"10.1038\/ncomms15533","article-title":"The genetic landscape of benign thyroid nodules revealed by whole exome and transcriptome sequencing","volume":"8","author":"Ye","year":"2017","journal-title":"Nat Commun."},{"key":"2021122204430246300_CIT0014","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3389\/fendo.2019.00438","article-title":"Analytical verification performance of afirma genomic sequencing classifier in the diagnosis of cytologically indeterminate thyroid nodules","volume":"10","author":"Hao","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"key":"2021122204430246300_CIT0015","first-page":"A105","article-title":"Clinical validation of the afirma genomic sequencing classifier for medullary thyroid cancer (Clinical Oral Abstract 29)","volume":"27","author":"Randolph","year":"2017","journal-title":"Thyroid"},{"key":"2021122204430246300_CIT0016","first-page":"A50","article-title":"Clinical validation of the afirma genomic sequencing parathyroid classifier (poster 168)","volume":"27","author":"Sosa","year":"2017","journal-title":"Thyroid"},{"key":"2021122204430246300_CIT0017","volume-title":"Data from: Supplemental Tables of: Afirma Genomic Sequencing Classifier & Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules","author":"Hu","year":"2021"},{"issue":"11","key":"2021122204430246300_CIT0018","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1089\/thy.2019.0278","article-title":"Molecular variants and their risks for malignancy in cytologically indeterminate thyroid nodules","volume":"29","author":"Goldner","year":"2019","journal-title":"Thyroid."},{"issue":"2","key":"2021122204430246300_CIT0019","doi-asserted-by":"crossref","first-page":"161","DOI":"10.4158\/EP-2018-0395","article-title":"Statistical comparison of Afirma GSC and Afirma GEC outcomes in a community endocrine surgical practice: early findings","volume":"25","author":"Harrell","year":"2019","journal-title":"Endocr Pract."},{"issue":"5","key":"2021122204430246300_CIT0020","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1089\/thy.2018.0726","article-title":"Independent comparison of the Afirma genomic sequencing classifier and gene expression classifier for cytologically indeterminate thyroid nodules","volume":"29","author":"Angell","year":"2019","journal-title":"Thyroid."},{"issue":"8","key":"2021122204430246300_CIT0021","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1089\/thy.2018.0733","article-title":"Afirma gene sequencing classifier compared with gene expression classifier in indeterminate thyroid nodules","volume":"29","author":"Endo","year":"2019","journal-title":"Thyroid."},{"issue":"11","key":"2021122204430246300_CIT0022","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/cncy.22188","article-title":"Performance of the Afirma genomic sequencing classifier versus gene expression classifier: an institutional experience","volume":"127","author":"Wei","year":"2019","journal-title":"Cancer Cytopathol."},{"issue":"3","key":"2021122204430246300_CIT0023","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz099","article-title":"Real-world comparison of afirma GEC and GSC for the assessment of cytologically indeterminate thyroid nodules","volume":"105","author":"San Martin","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2021122204430246300_CIT0024","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s12022-020-09604-7","article-title":"Testing for afirma in thyroid nodules with high-risk indeterminate cytology (TIR3B): first Italian experience","volume":"31","author":"Andrioli","year":"2020","journal-title":"Endocr Pathol."},{"issue":"1","key":"2021122204430246300_CIT0025","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamaoncol.2020.5935","article-title":"Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: a randomized clinical trial","volume":"7","author":"Livhits","year":"2021","journal-title":"JAMA Oncol."},{"issue":"2","key":"2021122204430246300_CIT0026","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/cyt.12920","article-title":"Comparison of Afirma gene expression classifier with gene sequencing classifier in indeterminate thyroid nodules: a single-institutional experience","volume":"32","author":"Geng","year":"2021","journal-title":"Cytopathology."},{"issue":"9","key":"2021122204430246300_CIT0027","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1089\/thy.2020.0021","article-title":"Letter to the editor: use of molecular diagnostic tests in thyroid nodules with h\u00fcrthle cell-dominant cytology","volume":"30","author":"Endo","year":"2020","journal-title":"Thyroid."},{"issue":"6","key":"2021122204430246300_CIT0028","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1002\/dc.23711","article-title":"Identification of parathyroid tissue in thyroid fine-needle aspiration: a combined approach using cytology, immunohistochemical, and molecular methods","volume":"45","author":"Domingo","year":"2017","journal-title":"Diagn Cytopathol."},{"issue":"2","key":"2021122204430246300_CIT0029","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/cen.12563","article-title":"Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis","volume":"82","author":"Trimboli","year":"2015","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"3","key":"2021122204430246300_CIT0030","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1002\/hed.26550","article-title":"Limitations of preoperative cytology for medullary thyroid cancer: proposal for improved preoperative diagnosis for optimal initial medullary thyroid carcinoma specific surgery","volume":"43","author":"Workman","year":"2021","journal-title":"Head Neck."},{"issue":"4","key":"2021122204430246300_CIT0031","doi-asserted-by":"crossref","first-page":"E761","DOI":"10.1210\/jc.2012-3762","article-title":"Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma gene expression classifier in cytologically indeterminate thyroid nodules?","volume":"98","author":"Kloos","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2021122204430246300_CIT0032","doi-asserted-by":"crossref","first-page":"e1006239","DOI":"10.1371\/journal.pgen.1006239","article-title":"Comprehensive analysis of the transcriptional and mutational landscape of follicular and papillary thyroid cancers","volume":"12","author":"Yoo","year":"2016","journal-title":"Plos Genet."},{"issue":"14","key":"2021122204430246300_CIT0033","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21144951","article-title":"Current and future role of tyrosine kinases inhibition in thyroid cancer: from biology to therapy","volume":"21","author":"San Roman Gil","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"8","key":"2021122204430246300_CIT0034","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med."},{"issue":"10","key":"2021122204430246300_CIT0035","doi-asserted-by":"crossref","first-page":"OF2","DOI":"10.1158\/2159-8290.CD-NB2019-101","article-title":"Entrectinib OK\u2019d for cancers with NTRK fusions, NSCLC","volume":"9","year":"2019","journal-title":"Cancer Discov"},{"issue":"11","key":"2021122204430246300_CIT0036","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40265-020-01343-7","article-title":"Selpercatinib: first approval","volume":"80","author":"Markham","year":"2020","journal-title":"Drugs."},{"issue":"9","key":"2021122204430246300_CIT0037","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"2021122204430246300_CIT0038","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1038\/s41379-020-0638-5","article-title":"Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization","volume":"33","author":"Chu","year":"2020","journal-title":"Mod Pathol."},{"issue":"11","key":"2021122204430246300_CIT0039","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/s41379-020-0574-4","article-title":"Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC)","volume":"33","author":"Chu","year":"2020","journal-title":"Mod Pathol."},{"issue":"5","key":"2021122204430246300_CIT0040","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1089\/thy.2015.0527","article-title":"Highly concordant key genetic alterations in primary tumors and matched distant metastases in differentiated thyroid cancer","volume":"26","author":"Sohn","year":"2016","journal-title":"Thyroid."},{"issue":"1","key":"2021122204430246300_CIT0041","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1089\/thy.2019.0052","article-title":"Whole-exome sequencing of matched primary and metastatic papillary thyroid cancer","volume":"30","author":"Masoodi","year":"2020","journal-title":"Thyroid."},{"issue":"11","key":"2021122204430246300_CIT0042","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1089\/thy.2019.0459","article-title":"Risk stratification using a novel genetic classifier including PLEKHS1 promoter mutations for differentiated thyroid cancer with distant metastasis","volume":"30","author":"Jung","year":"2020","journal-title":"Thyroid."},{"issue":"2","key":"2021122204430246300_CIT0043","doi-asserted-by":"crossref","first-page":"E364","DOI":"10.1210\/jc.2012-2703","article-title":"Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS","volume":"98","author":"Agrawal","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2021122204430246300_CIT0044","doi-asserted-by":"crossref","first-page":"R235","DOI":"10.1530\/ERC-15-0070","article-title":"RAS proto-oncogene in medullary thyroid carcinoma","volume":"22","author":"Moura","year":"2015","journal-title":"Endocr Relat Cancer."},{"issue":"7","key":"2021122204430246300_CIT0045","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/2159-8290.CD-NB2020-052","article-title":"FDA approves selpercatinib; pralsetinib may soon follow","volume":"10","year":"2020","journal-title":"Cancer Discov"},{"issue":"6","key":"2021122204430246300_CIT0046","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid."},{"issue":"6","key":"2021122204430246300_CIT0047","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1089\/thy.2016.0001","article-title":"A genomic alternative to identify medullary thyroid cancer preoperatively in thyroid nodules with indeterminate cytology","volume":"26","author":"Kloos","year":"2016","journal-title":"Thyroid."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab304\/38614659\/dgab304.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/8\/2198\/41847874\/dgab304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/8\/2198\/41847874\/dgab304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T04:47:51Z","timestamp":1640148471000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/8\/2198\/6278308"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,5,19]]},"published-print":{"date-parts":[[2021,7,13]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab304","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,8,1]]},"published":{"date-parts":[[2021,5,19]]}}}